Gini Fleming
Section of Hematology / Oncology
Professor of Medicine
Director, Medical Oncology of Breast and Gynecologic Cancer Program
Referring Physician Access Line: 1-877-DOM-2730


BA1981Oberlin CollegeChemistry
MD1985University of Illinois 
Residency1988The University of ChicagoInternal Medicine
Fellowship1992The University of ChicagoHematology/Oncology

Academic Interests

Dr. Fleming works with clinical trials to develop new agents for the therapy of breast and gynecologic cancers.

Clinical Interests

Gynecologic cancer, breast cancer

Representative Publications

  1. Fleming GF, Meropol NJ, Rosner GL, Hollis DR, Carson WE, III, Caligiuri M, Mortimer J, Tkaczuk K, Parihar R, Schilsky RL, Ratain MJ. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin-2. Clin Cancer Res 8:3718-3727, 2002.
  2. Fleming GF, Schilsky RL, Schumm LP, Meyerson A, Hong AM, Vogelzang NJ, Ratain MJ. Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with hepatic or renal dysfunction. Ann Oncol 14:1142-1147, 2003.
  3. Mundt AJ, Rotmensch J, Waggoner SE, Yamada SD, Fleming GF. Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies. Gynecol Oncol 92:801-805, 2004.
  4. Fleming GF, Brunetto VL, Cella D, Look KY, Reid G, Munkarah AR, Kline R, Burger RA, Goodman AN, Burks RT. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol.22:2159-2166,2004
  5. Fleming GF, Filiaci VL, Bentley RC, Herzog T, Sorosky J, Vaccarello L, Gallion H. Phase III randomized study of doxorubicin + cisplatin versus doxorubicin + 24-hour paclitaxel + filgrastim in patients with stage III, IV or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Ann Oncol.8:1173-8,2004

More Information

For more information about Dr. Gini Fleming publications and research collaborations , please click here